| Identification | Back Directory | [Name]
(2S,4R)-1-[(S)-2-(tert-Butyl)-23-[[2-[4-(methylamino)phenyl]-6-benzothiazolyl]oxy]-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosan-1-oyl]-4-hydroxy-N-[(S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]pyrrolidine-2-carboxamide | [CAS]
2412273-77-7 | [Synonyms]
(2S,4R)-1-[(S)-2-(tert-Butyl)-23-[[2-[4-(methylamino)phenyl]-6-benzothiazolyl]oxy]-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosan-1-oyl]-4-hydroxy-N-[(S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]pyrrolidine-2-carboxamide | [Molecular Formula]
C51H68N6O11S2 | [MOL File]
2412273-77-7.mol | [Molecular Weight]
1005.25 |
| Chemical Properties | Back Directory | [density ]
1.254±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
13.540±0.46(predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
PROTAC α-synuclein degrader 3 (Compound 5) is a selective α-synuclein PROTAC degrader. PROTAC α-synuclein degrader 3 can promote the ubiquitination and degradation of α-synuclein. PROTAC α-synuclein degrader 3 can be used for Parkinson's disease research[1]. | [IC 50]
α-synuclein | [References]
[1] Andrew PC, et, al. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases. WO2020041331A1. |
|
|